研究業績 Publications

[原著論文]

  1. Nguyen HN, Suzuki K, Kimura Y, Hirokawa T, Murakami-Tonami Y, Abe H.,Synthesis and Biological Evaluation of NMDI-14 Derivatives as anti-Mesothelioma Agents., Heterocycles, 100 (2): 253-266, 2020
  2. Shishido Y, Tomoike F, Kuwata K, Fujikawa H, Sekido Y, Murakami-Tonami Y, Kameda T, Abe N, Kimura Y, Shuto S, Abe H., A Covalent Inhibitor for Glutathione S‐Transferase Pi (GSTP1‐1) in Human Cells., ChemBioChem20 (7):900-905, 2019
  3. Shishido Y, Tomoike F, Kimura Y, Kuwata K, Yano T, Fukui K, Fujikawa H, Sekido Y, Murakami-Tonami Y, Kameda T, Shuto S, Abe H., A Covalent G-site Inhibitor for Glutathione S-Transferase Pi (GSTP1-1)., Chem. Comm.53 (81), 11138-11141, 2017
  4. Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y., Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis., Cancer Letters385; 215-224, 2017
  5. Murakami-Tonami Y*, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, Komata Y, Koster J, Takeuchi I, Kondo Y, Maeda T, Sekido Y, Murakami H, Kadomatsu K*., SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells., Sci Rep31615, 2016. *: corresponding authors
  6. Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, Sekido Y., Functional differences between wild-type and mutant-type BAP1 tumor suppressor against malignant mesothelioma cells.,  Cancer Science, 106 (8) 990-99, 2015.
  7. Nakaguro M, Kiyonari S, Kishida S, Cao D, Murakami-Tonami Y, Ichikawa H, Takeuchi I, Nakamura S, Kadomatsu K., The nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation., Cancer Science106 (3) 237-43, 2015.
  8. Murakami-Tonami Y, Ohtsuka H, Aiba H, Murakami H., Regulation of wee1+ expression during meiosis in fission yeast., Cell Cycle13 (18) : 2853-2858, 2014. 
  9. Murakami-Tonami Y*, Kishida S, Takeuchi I, Katou Y, Maris JM, Ichikawa H, Kondo Y, Sekido Y, Shirahige K, Murakami H, Kadomatsu K*., Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells., Cell Cycle13 (7) : 1115-31, 2014. *: corresponding authors
  10. duVerle D, Takeuchi I, Murakami-Tonami Y, Kadomatsu K, Tsuda K., Discovering Combinatorial Interactions in Survival Data., Bioinformatics29 (23) : 3053-9, 2013
  11. Akai Y, Kurokawa Y, Nakazawa N, Tonami-Murakami Y, Suzuki Y, Yoshimura SH, Iwasaki H, Shiroiwa Y, Nakamura T, Shibata E and Yanagida M., Opposing role of condensin hinge against replication protein A in mitosis and interphase through promoting DNA annealing., Open Biol. 1: 110023, 2011
  12. Huang P, Kishida S, Cao D, Murakami-Tonami Y, Mu P, Nakaguro M, Koide N, Takeuchi I, Onishi A, Kadomatsu K., The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent  factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma., Cancer Res. 71, pp.2938-48, 2011
  13. Shimada M, Yamamoto A, Murakami-Tonami Y, Nakanishi M, Yoshida T, Aiba H, Murakami H., Casein kinase II is required for the spindle assembly checkpoint by regulating Mad2p in fission yeast., Biochem Biophys Res Commun388, pp.529-32, 2009
  14. Shimada M, Namikawa-Yamada C, Murakami-Tonami Y, Yoshida T, Nakanishi M, Urano T, and Murakami H., Cdc2p controls the forkhead transcription factor Fkh2p by phosphorylation during sexual differentiation in fission yeast., EMBO J 27, pp.132-142, 2008
  15. Murakami-Tonami Y, Yamada-Namikawa C, Tochigi A, Hasegawa N, Kojima H, Kunimatsu M, Nakanishi M and Murakami H., Mei4p coordinates the onset of meiosis I by regulating cdc25+ in fission yeast., Proc Natl Acad Sci U S A. 104, pp.14688-14693, 2007
  16. Tonami Y, Murakami H, Shirahige K, Nakanishi M., A checkpoint control linking meiotic S phase and recombination initiation in fission yeast., Proc Natl Acad Sci U S A. 102, pp.5797-5801, 2005
  17. Sugimoto I, Murakami H, Tonami Y, Moriyama A, Nakanishi M., DNA replication checkpoint control mediated by the spindle checkpoint protein Mad2p in fission yeast., J Biol Chem. 279, pp.47372-8, 2004

[英文総説] 

  1. Murakami-Tonami Y., Synthetic lethality in the search for novel molecular targets in cancer therapeutics. Juntendo Medical Journal, 65 (3), 292-296, 2019
  2. Murakami H, Aiba H, Nakanishi M and Murakami-Tonami Y., Regulation of yeast forkhead transcription factors and FoxM1 by cyclin-dependent and Polo-like kinases., Cell cycle9, pp.3233-3242, 2010

[和文総説] 

  1.  渡並優子, 村上浩士, 中西真., 分裂酵母・出芽酵母における減数分裂の細胞周期制御機構., 実験医学(羊土社), 20 (4) , 546-551, 2002

[著書] 

  1. 渡並優子,中西真., 実験医学増刊 細胞周期研究のフロンティア(監修: 西本毅治, 編著:中山敬一, 正井久雄, 佐方功幸), 執筆担当部分「4.1哺乳動物細胞におけるDNA傷害および複製チェックポイント」, 羊土社,  18 (7) , 152-157, 2000
  2. 渡並優子, 中西真., BioScience新用語ライブラリー 細胞周期 第2版(編著: 田矢洋一, 花岡文雄, 野島博), 執筆担当部分「Chk1/Chk2(Cds1)」, 羊土社, 140-141, 1999
  3. 渡並優子,名嶋弥菜,中西真., 別冊医学のあゆみ 老化のメカニズムを探る(編著: 石川冬木), 執筆担当部分「6. 老化細胞における細胞周期制御異常」, 医歯薬出版, 188(1) , 31-35, 1999

[招待講演]

  1. NAGOYAグローバルリトリート(2017.2.10. 大府健康プラザ)’The relationship between DNA damage response and MYCN amplification in neuroblastoma cells’
  2. 薬学会東海支部特別講演会 (2014.7.16. 名古屋) ‘MYCN増幅と合成致死表現型を示す遺伝子の探索〜神経芽腫をモデルとして’ 

[特許]

  1. 出願番号:特願2019-210554
    発明者:村上優子・佐藤綾人・三井田孝・関戸好孝
    発明の名称:悪性中皮腫の治療剤
    出願人:順天堂大学、国立大学法人名古屋大学、愛知県
    出願日:2019年11月21日
  2. 出願番号:特願2019-191790
    発明者:村上優子・鈴木浩也・三井田孝・関戸好孝・向井智美・山岸良多
    発明の名称:LATS2変異疾患のための分子標的及びその利用
    出願人:順天堂大学、愛知県
    出願日:2019年10月21日
  3. 出願番号:特願2012-104857
    発明者:門松健治・村上優子
    発明の名称:MYCN増幅型疾患のための分子標的及びその利用
    出願人:国立大学法人名古屋大学
    出願日:2012年5月1日